Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTIVATE
2024-511325-67-00Phase 3Withdrawn
- Sponsor
- The George Institute for Global Health
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised trial in chronic kidney disease (CKD) comparing Finerenone arm with Placebo arm (2 arms). Primary endpoint: eGFR slope from randomisation to week 108. Planned start Nov 2024; status: withdrawn.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-511325-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511325-67-00.